,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2015', 'fs': 'Feb 2015', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvP2AT'}, 'Id': 'a0POZ00000FStvP2AT', 'Event_Date__c': '2015-02-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2015', 'Status_History__c': 'a132P000000Aqr8QAC'}, 'change': None}]",Feb 2015,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': '<p>1.14 The Subcommittee noted a new UK Medical Research Council (UK MRC) cooperative group trial, AML-19, for younger adults with favourable and intermediate-risk acute myeloid leukaemia (AML) that was to commence enrolment in New Zealand shortly. Members noted that participating in the series of prior AML studies over time had significantly increased cure rates in New Zealand from 10% to around 50% and continued participation in such trials was the standard of care approach and would likely lead to further health gains. </p><p>1.15 The Subcommittee noted that whilst several arms of the AML-19 included new investigational agents, provided free of charge by various pharmaceutical companies, one arm required treatment with gemtuzumab ozogamicin (Mylotarg, GO) which was not provided as it was considered a standard of care treatment overseas. </p><p>1.16 The Subcommittee considered that is was very important that New Zealand patients and centres should be able to participate in AML-19. Members noted that for haematologists participating in this study this would be a higher priority than some of the outstanding new funding applications. The Subcommittee recommended that gemtuzumab ozogamicin should be considered for listing on the Pharmaceutical Schedule. </p><p>1.17 The Subcommittee noted that it was very supportive of New Zealand centres and patients participating in clinical trials and recommended that PHARMAC develop a mechanism for funding treatments for non-industry clinical trials. Members considered that setting up a contestable fund for clinical trial treatment funding may be a reasonable approach</p>', 'fs': '<p>1.14 The Subcommittee noted a new UK Medical Research Council (UK MRC) cooperative group trial, AML-19, for younger adults with favourable and intermediate-risk acute myeloid leukaemia (AML) that was to commence enrolment in New Zealand shortly. Members noted that participating in the series of prior AML studies over time had significantly increased cure rates in New Zealand from 10% to around 50% and continued participation in such trials was the standard of care approach and would likely lead to further health gains. </p><p>1.15 The Subcommittee noted that whilst several arms of the AML-19 included new investigational agents, provided free of charge by various pharmaceutical companies, one arm required treatment with gemtuzumab ozogamicin (Mylotarg, GO) which was not provided as it was considered a standard of care treatment overseas. </p><p>1.16 The Subcommittee considered that is was very important that New Zealand patients and centres should be able to participate in AML-19. Members noted that for haematologists participating in this study this would be a higher priority than some of the outstanding new funding applications. The Subcommittee recommended that gemtuzumab ozogamicin should be considered for listing on the Pharmaceutical Schedule. </p><p>1.17 The Subcommittee noted that it was very supportive of New Zealand centres and patients participating in clinical trials and recommended that PHARMAC develop a mechanism for funding treatments for non-industry clinical trials. Members considered that setting up a contestable fund for clinical trial treatment funding may be a reasonable approach</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 20 March 2015.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 20 March 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvQ2AT'}, 'Id': 'a0POZ00000FStvQ2AT', 'Event_Date__c': '2015-03-20', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 20 March 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatments-subcommittee-minutes-2015-03.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': '<p>1.14 The Subcommittee noted a new UK Medical Research Council (UK MRC) cooperative group trial, AML-19, for younger adults with favourable and intermediate-risk acute myeloid leukaemia (AML) that was to commence enrolment in New Zealand shortly. Members noted that participating in the series of prior AML studies over time had significantly increased cure rates in New Zealand from 10% to around 50% and continued participation in such trials was the standard of care approach and would likely lead to further health gains. </p><p>1.15 The Subcommittee noted that whilst several arms of the AML-19 included new investigational agents, provided free of charge by various pharmaceutical companies, one arm required treatment with gemtuzumab ozogamicin (Mylotarg, GO) which was not provided as it was considered a standard of care treatment overseas. </p><p>1.16 The Subcommittee considered that is was very important that New Zealand patients and centres should be able to participate in AML-19. Members noted that for haematologists participating in this study this would be a higher priority than some of the outstanding new funding applications. The Subcommittee recommended that gemtuzumab ozogamicin should be considered for listing on the Pharmaceutical Schedule. </p><p>1.17 The Subcommittee noted that it was very supportive of New Zealand centres and patients participating in clinical trials and recommended that PHARMAC develop a mechanism for funding treatments for non-industry clinical trials. Members considered that setting up a contestable fund for clinical trial treatment funding may be a reasonable approach</p>', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqsyQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvR2AT'}, 'Id': 'a0POZ00000FStvR2AT', 'Event_Date__c': '2015-05-07', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AquhQAC'}, 'change': None}, {'Summary': {'s': '<p>Recommendation:</p><p>6.2. The Committee <b>recommended </b>that funding of gemtuzumab ozogamicin on the Pharmaceutical Schedule for the treatment of favourable and intermediate-risk acute myeloid leukaemia be declined. </p><p>6.3. The Committee noted that all members were supportive of NZ centres and patients participating in the AML-19 trial and decisions about funding of pharmaceuticals in the context of participation in clinical trials are difficult. Some members of the Committee were of the opinion that unfunded clinical trial treatments should not be funded from the Combined Pharmaceuticals Budget because there are other potential sources of funding to support clinical trials in New Zealand. Members considered PHARMAC should grant a Hospital Medicines List (HML) exemption to enable DHBs to fund gemtuzumab ozogamicin for patients enrolled in the AML-19 clinical trial should the individual DHBs wish to do so. </p><p>6.4. The Committee reiterated its previous recommendation that PHARMAC review the mechanisms through which unfunded clinical trial treatments including paediatric oncology treatments are considered and funded.</p><p>6.5. The Decision Criteria particularly relevant to this recommendation are: (i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.\xa0</p>', 'fs': '<p>Recommendation:</p><p>6.2. The Committee <b>recommended </b>that funding of gemtuzumab ozogamicin on the Pharmaceutical Schedule for the treatment of favourable and intermediate-risk acute myeloid leukaemia be declined. </p><p>6.3. The Committee noted that all members were supportive of NZ centres and patients participating in the AML-19 trial and decisions about funding of pharmaceuticals in the context of participation in clinical trials are difficult. Some members of the Committee were of the opinion that unfunded clinical trial treatments should not be funded from the Combined Pharmaceuticals Budget because there are other potential sources of funding to support clinical trials in New Zealand. Members considered PHARMAC should grant a Hospital Medicines List (HML) exemption to enable DHBs to fund gemtuzumab ozogamicin for patients enrolled in the AML-19 clinical trial should the individual DHBs wish to do so. </p><p>6.4. The Committee reiterated its previous recommendation that PHARMAC review the mechanisms through which unfunded clinical trial treatments including paediatric oncology treatments are considered and funded.</p><p>6.5. The Decision Criteria particularly relevant to this recommendation are: (i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.\xa0</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvS2AT'}, 'Id': 'a0POZ00000FStvS2AT', 'Event_Date__c': '2015-05-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': '<p>Recommendation:</p><p>6.2. The Committee <b>recommended </b>that funding of gemtuzumab ozogamicin on the Pharmaceutical Schedule for the treatment of favourable and intermediate-risk acute myeloid leukaemia be declined. </p><p>6.3. The Committee noted that all members were supportive of NZ centres and patients participating in the AML-19 trial and decisions about funding of pharmaceuticals in the context of participation in clinical trials are difficult. Some members of the Committee were of the opinion that unfunded clinical trial treatments should not be funded from the Combined Pharmaceuticals Budget because there are other potential sources of funding to support clinical trials in New Zealand. Members considered PHARMAC should grant a Hospital Medicines List (HML) exemption to enable DHBs to fund gemtuzumab ozogamicin for patients enrolled in the AML-19 clinical trial should the individual DHBs wish to do so. </p><p>6.4. The Committee reiterated its previous recommendation that PHARMAC review the mechanisms through which unfunded clinical trial treatments including paediatric oncology treatments are considered and funded.</p><p>6.5. The Decision Criteria particularly relevant to this recommendation are: (i) The health needs of all eligible people within New Zealand; (iii) The availability and suitability of existing medicines, therapeutic medical devices and related products and related things; (iv) The clinical benefits and risks of pharmaceuticals.\xa0</p>', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AqurQAC'}, 'change': None}]",Mar 2015,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvT2AT'}, 'Id': 'a0POZ00000FStvT2AT', 'Event_Date__c': '2015-05-08', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AqvbQAC'}, 'change': None}]",May 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2015', 'fs': 'Sep 2015', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvU2AT'}, 'Id': 'a0POZ00000FStvU2AT', 'Event_Date__c': '2015-09-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2015', 'Status_History__c': 'a132P000000AqzHQAS'}, 'change': None}, {'Summary': {'s': '<p><span style=""font-size: 14px;"">A separate funding application was subsequently received for routine Gemtuzumab use in NZ clinical practice.\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000A613f/p001533"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">That application</a><span style=""font-size: 14px;"">\xa0supersedes this one.</span></p>', 'fs': '<p><span style=""font-size: 14px;"">A separate funding application was subsequently received for routine Gemtuzumab use in NZ clinical practice.\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000A613f/p001533"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">That application</a><span style=""font-size: 14px;"">\xa0supersedes this one.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvV2AT'}, 'Id': 'a0POZ00000FStvV2AT', 'Event_Date__c': '2020-07-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Summary__c': '<p><span style=""font-size: 14px;"">A separate funding application was subsequently received for routine Gemtuzumab use in NZ clinical practice.\xa0</span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000A613f/p001533"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">That application</a><span style=""font-size: 14px;"">\xa0supersedes this one.</span></p>', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000ESDDQA4'}, 'change': None}]",Sep 2015,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvW2AT'}, 'Id': 'a0POZ00000FStvW2AT', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FThCFYA1'}, 'change': None}]",Oct 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FStvX2AT'}, 'Id': 'a0POZ00000FStvX2AT', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCi5DYAT'}, 'change': None}]",Nov 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
